KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Asset Writedowns and Impairment (2016 - 2022)

Travere Therapeutics (TVTX) has disclosed Asset Writedowns and Impairment for 7 consecutive years, with -$1.0 million as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Asset Writedowns and Impairment fell 17.96% year-over-year to -$1.0 million, compared with a TTM value of $1.0 million through Dec 2022, up 108.63%, and an annual FY2025 reading of $684000.0, down 75.74% over the prior year.
  • Asset Writedowns and Impairment was -$1.0 million for Q4 2022 at Travere Therapeutics, down from $329000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $25.5 million in Q1 2019 and bottomed at -$1.0 million in Q4 2022.
  • Average Asset Writedowns and Impairment over 4 years is $2.9 million, with a median of $481000.0 recorded in 2021.
  • The sharpest move saw Asset Writedowns and Impairment tumbled 139.28% in 2021, then surged 94.87% in 2022.
  • Year by year, Asset Writedowns and Impairment stood at $25.5 million in 2019, then plummeted by 91.27% to $2.2 million in 2020, then crashed by 139.28% to -$874000.0 in 2021, then decreased by 17.96% to -$1.0 million in 2022.
  • Business Quant data shows Asset Writedowns and Impairment for TVTX at -$1.0 million in Q4 2022, $329000.0 in Q3 2022, and $792000.0 in Q2 2022.